Methods and materials for reducing amyloid beta levels within a mammal

• US 10,639,322 B2
• Filed: 03/25/2016
• Issued: 05/05/2020
• Est. Priority Date: 03/27/2015
• Status: Active Grant

• Current Assignee: The Research Foundation for The State University of New York (State University of New York)
• Original Assignee: The Research Foundation for The State University of New York (State University of New York)
• Inventors: Stefano, George B., Kream, Richard M., Mantione, Kirk J.
• Primary Examiner(s): Berry, Layla D
• Application Number:
  US15/562,149
• Publication Number:
  US 20180078575A1
• Time in Patent Office: 1,502 Days
• Field of Search: None
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/385 having two or more sulfur atoms in the same ring
• CPC Class Codes: A61K 31/718 Starch or degraded starch, e.g. amylose, amylopectin
• CPC Class Codes: A61K 36/81 Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

This document provides methods and materials for reducing amyloid beta levels within a mammal (e.g. a mammal having Alzheimer'"'"'s disease). For example, this document provides methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of Alzheimer'"'"'s disease. In some cases, a composition containing a potato polysaccharide preparation provided herein can be used to increase binding, sequestration, and/or degradation of CNS-derived amyloid beta polypeptides, thereby inhibiting the formation of neurofibrillary plaques.

Claims

1. A method for reducing amyloid beta levels within a mammal having Alzheimer'"'"'s disease, wherein said method comprises administering to said mammal a composition comprising a potato polysaccharide preparation obtained from raw potatoes, wherein said potato polysaccharide preparation, when derivatized, results in at least the following acylated carbohydrates as assessed using gas chromatography/mass spectography:

(a) myo-inositol, set to 1x to serve as an internal standard,

(b) glucose at about 40X to about 60X the myo-inositol content,

(c) xylose at about 10X to about 20X the myo-inositol content,

(d) mannose at about 5X to about 15X the myo-inositol content, and

(e) galactose at about 3X to about 7X the myo-inositol content,

wherein the level of amyloid beta within said mammal is reduced.

2. The method of claim 1, wherein said mammal is a human.

3. The method of claim 1, wherein said level of amyloid beta within said mammal is reduced in blood.

4. The method of claim 1, wherein said level of amyloid beta within said mammal is reduced in adipose tissue.

5. The method of claim 1, wherein said composition comprises said potato polysaccharide preparation in an amount that results in between 0.05 mg and 50 mg of the potato polysaccharide component of said potato polysaccharide preparation being administered to said mammal per kg of body weight of said mammal.

6. The method of claim 1, wherein said composition comprises between 1 mg and 100 mg of said potato polysaccharide preparation.

7. The method of claim 1, wherein said composition comprises between 6 mg and 20 mg of said potato polysaccharide preparation.

8. The method of claim 1, wherein said composition comprises between 1 mg and 100 mg of the potato polysaccharide component of said potato polysaccharide preparation.

9. The method of claim 1, wherein said composition comprises between 6 mg and 20 mg of the potato polysaccharide component of said potato polysaccharide preparation.

10. The method of claim 1, wherein said composition is in the form of a tablet.

11. The method of claim 1, wherein said composition comprises alpha lipoic acid.

12. The method of claim 1, wherein said composition comprises alpha tocopherol.

13. The method of claim 1, wherein said potato polysaccharide preparation is in an amount that results in between 0.075 mg and 0.5 mg of the potato polysaccharide component of said potato polysaccharide preparation being administered to said mammal per kg of body weight of said mammal.

14. The method of claim 1, wherein at least about 80 percent of said potato polysaccharide preparation is potato polysaccharide.

15. The method of claim 1, wherein at least about 90 percent of said potato polysaccharide preparation is potato polysaccharide.

16. The method of claim 1, wherein at least about 95 percent of said potato polysaccharide preparation is potato polysaccharide.